TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01956721

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise training,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training,

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Study: NCT02730013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Square Stepping Exercise
Description: Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
Study: NCT03293368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
Study: NCT05178719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMA-zeolite
Description: given for a total period of 4 years
Study: NCT04680182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction drain
Description: Suction drain either kept for three weeks or gradually pulled out.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction drain
Description: Suction drain either kept for three weeks or gradually pulled out.
Study: NCT00629889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.
Study: NCT01932437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204
Study: NCT03620227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
Study: NCT04655443

Intervention type: OTHER
Intervention: Standard Care
Description: Standard cardiovascular care

Intervention type: OTHER
Intervention: Standard Care
Description: Standard cardiovascular care
Study: NCT00663988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human transplantation
Description: Allograft composite tissue transplantation. procedure. medication
Study: NCT00513500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coartem and amoxicillin
Description: Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Give Coartem without RDT and refer fast breathing
Study: NCT03631732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third Agent
Description: Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)
Study: NCT04963556

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Red Bull
Description: Drinking of Red Bull before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Bull
Description: Drinking of Red Bull before exercise
Study: NCT01640314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell derived subunit trivalent nonadjuvanted vaccine
Description: A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
Study: NCT00330902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
Description: sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine (PQ) plus SP+AS
Description: single dose of primaquine on day 4
Study: NCT00385632

Intervention type: DRUG
Intervention: Antiretroviral Regimens
Description: Various antiretroviral therapy combinations already being administered to participants

Intervention type: DRUG
Intervention: Antiretroviral Regimens
Description: Various antiretroviral therapy combinations already being administered to participants
Study: NCT03051360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 Inhibitor [EPC]
Description: Patients will receive PCSK9 inhibitor by a biweekly injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive Placebo by a biweekly injection
Study: NCT03784976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga Therapy
Description: 2 weekly yoga class (1.25 hours each)
Study: NCT02463175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Boluses of 5ml/kg of plasmalyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Boluses of 5ml/kg of plasmalyte

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT)
Description: Intraoperative goal-directed fluid therapy (GDT)
Study: NCT04356560

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test, polymerase chain reaction for SARS-CoV-2
Description: surveillance
Study: NCT02611089

Intervention type: PROCEDURE
Intervention: Tissue biopsy
Description: Sampling of tissue as described.

Intervention type: PROCEDURE
Intervention: Tissue biopsy
Description: Sampling of tissue as described.
Study: NCT03061981

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.

Intervention type: DRUG
Group type: OTHER
Intervention: DA-1241
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-1241
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
Study: NCT03043248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700
Description: repeated oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700
Description: repeated oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single oral administration with/without TRK-700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single oral administration with/without TRK-700
Study: NCT02510027

Intervention type: OTHER
Intervention: HPV screening and triage tests
Description: All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
Study: NCT02194127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthocyan capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03869359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with gluten powder
Description: The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with gluten powder
Description: The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with placebo powder
Description: The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with placebo powder
Description: The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
Study: NCT04133532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: metoprolol 50 mg daily for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: metoprolol 50 mg daily for three months
Study: NCT01776515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride/Acetaminophen Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/Acetaminophen SR Tab.
Study: NCT00385255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix®
Description: GSK Biologicals' inactivated influenza split virus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix®
Description: GSK Biologicals' inactivated influenza split virus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
Study: NCT04304716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
Study: NCT01825707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-YH4808 200 mg
Description: \[14C\]-YH4808 200 mg (oral) on day1
Study: NCT01277549

Intervention type: DEVICE
Intervention: Mononuclear cell collection.
Description: Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.

Intervention type: DEVICE
Intervention: Mononuclear cell collection.
Description: Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
Study: NCT02657408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00583362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 10mg/kg IV over one hour every 28 days
Study: NCT03672097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel, oral tablets, containing 3.75 mg per tablet
Study: NCT03346642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVD chemotherapy
Description: GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
Study: NCT01040234

Intervention type: PROCEDURE
Intervention: Bilateral dual TAP block
Description: Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
Study: NCT03288909

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI
Study: NCT02806583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured support groups
Description: Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
Study: NCT03961503

Intervention type: DRUG
Intervention: Daptomycin (DAP) treatment
Description: Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.

Intervention type: DRUG
Intervention: Vancomycin (VAN) treatment
Description: Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
Study: NCT02115204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study: NCT02995109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT05979298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapeutics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapeutics

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELENAGEN
Description: DNA plasmid
Study: NCT04455880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity
Description: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity
Description: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity
Description: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
Study: NCT02451215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy (LITT)
Description: Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.